UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

8-Hydroxydeoxyguanosine: a new potential independent prognostic factor in breast cancer

British journal of cancer, 2010-03, Vol.102 (6), p.1018-1023

2010

Volltextzugriff (PDF)

The role of metformin and statins in the incidence of epithelial ovarian cancer in type 2 diabetes: a cohort and nested case–control study

BJOG : an international journal of obstetrics and gynaecology, 2018-07, Vol.125 (8), p.1001-1008

2018

Volltextzugriff (PDF)

Absence of the DNA repair enzyme human 8-oxoguanine glycosylase is associated with an aggressive breast cancer phenotype

British journal of cancer, 2012-01, Vol.106 (2), p.344-347

2012

Volltextzugriff (PDF)

Cause-specific mortality in endometrioid endometrial cancer patients with type 2 diabetes using metformin or other types of antidiabetic medication

Gynecologic oncology, 2017-12, Vol.147 (3), p.678-683

2017

Volltextzugriff (PDF)

Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor

Gynecologic oncology, 2005-12, Vol.99 (3), p.656-663

2005

Volltextzugriff (PDF)

Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer

Gynecologic oncology, 2007-02, Vol.104 (2), p.296-303

2007

Volltextzugriff (PDF)

Expression of transmembrane carbonic anhydrases IX and XII in ovarian tumours

Histopathology, 2006-12, Vol.49 (6), p.594-602

2006

Volltextzugriff (PDF)

Matrix metalloproteinases‐2 and ‐9 in cervical cancer: different roles in tumor progression

International journal of gynecological cancer, 2006-05, Vol.16 (3), p.1297-1302

2006

Volltextzugriff (PDF)

Prognostic Significance of Extracellular Matrix Metalloproteinase Inducer and Matrix Metalloproteinase 2 in Epithelial Ovarian Cancer

Tumor biology, 2007-01, Vol.28 (5), p.280-289

2007

Volltextzugriff (PDF)

Evidence of Founder Mutations in Finnish BRCA1 and BRCA2 Families

American journal of human genetics, 1998-06, Vol.62 (6), p.1544-1548

1998

Volltextzugriff (PDF)

Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial

The lancet oncology, 2009-02, Vol.10 (2), p.135-146

2009

Volltextzugriff (PDF)

0235: Targeting Bevacizumab Treatment in Gynecological Malignancies

International journal of gynecological cancer, 2006-10, Vol.16 (Suppl 3), p.667-667

2006

Volltextzugriff (PDF)

Matrix metalloproteinase 9 and relapse in patients with early stage squamous cervical carcinoma

International journal of gynecology and obstetrics, 2005-10, Vol.91 (1), p.75-76

2005

Volltextzugriff (PDF)

0710: Surveillance of Women at High Risk of Gynecological Cancers: 10 Year Results From One Center

International journal of gynecological cancer, 2006-10, Vol.16 (Suppl 3), p.799-799

2006

Volltextzugriff (PDF)

Further evidence for the contribution of the RAD51C gene in hereditary breast and ovarian cancer susceptibility

Breast cancer research and treatment, 2011-12, Vol.130 (3), p.1003-1010

2011

Volltextzugriff (PDF)

FINHYST 2006—national prospective 1-year survey of 5 279 hysterectomies

Human reproduction (Oxford), 2009-10, Vol.24 (10), p.2515-2522

2009

Volltextzugriff (PDF)

Matrix metalloproteinases-2 and -9 in cervical cancer: different roles in tumor progression

International journal of gynecological cancer, 2006-04, Vol.16 (3), p.1297-1302

2006

Volltextzugriff (PDF)

Extracellular matrix interactions in early human embryos: implications for normal implantation events

Fertility and sterility, 1995-07, Vol.64 (1), p.132-138

1995

Volltextzugriff (PDF)

0076: Primary Surgery at University Hospitals Improves Survival of Ovarian Cancer-A Prospective Nationwide Study in Finland

International journal of gynecological cancer, 2006-10, Vol.16 (Suppl 3), p.621-621

2006

Volltextzugriff (PDF)

Gelatinases A and B (MMP-2 and MMP-9) in endometrial cancer—MMP-9 correlates to the grade and the stage

Gynecologic oncology, 2004-09, Vol.94 (3), p.699-704

2004

Volltextzugriff (PDF)

Laminin in the human embryo implantation: analogy to the invasion by malignant cells

Fertility and sterility, 1992-07, Vol.58 (1), p.105-113

1992

Volltextzugriff (PDF)

Regulation of 72-kd type IV collagenase-matrix metalloproteinase-2 by estradiol and gonadotropin-releasing hormone agonist in human granulosa-lutein cells

Fertility and sterility, 1995-07, Vol.64 (1), p.81-87

1995

Volltextzugriff (PDF)

SEQUENTIAL GEMCITABINE-CARBOPLATIN (GC) FOLLOWED BY PACLITAXEL-CARBOPLATIN (PC) IN THE FIRST-LINE TREATMENT OF ADVANCED OVARIAN CANCER (OC). A PHASE II TRIAL

International journal of gynecological cancer, 2004-09, Vol.14 (Suppl 1), p.31-31

2004

Volltextzugriff (PDF)

Randomized Trial of Single Agent Paclitaxel Given Weekly Versus Every Three Weeks and with Peroral Versus Intravenous Steroid Premedication to Patients with Ovarian Cancer Previously Treated with Platinum

Acta oncologica, 2002, Vol.41 (5), p.418-424

2002

Volltextzugriff (PDF)

Surgical treatment of ovarian cancer in different hospital categories – A prospective nation-wide study in Finland

European journal of cancer (1990), 2006-02, Vol.42 (3), p.388-395

2006

Volltextzugriff (PDF)

1 – 25 von 71

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(65)
Mit Volltextzugriff
(65)

Publikationsform

Artikel
(70)
magazinearticle
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

8-Hydroxydeoxyguanosine: a new potential independent prognostic factor in breast cancer

The role of metformin and statins in the incidence of epithelial ovarian cancer in type 2 diabetes: a cohort and nested case–control study

Absence of the DNA repair enzyme human 8-oxoguanine glycosylase is associated with an aggressive breast cancer phenotype

Cause-specific mortality in endometrioid endometrial cancer patients with type 2 diabetes using metformin or other types of antidiabetic medication

Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor

Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer

Expression of transmembrane carbonic anhydrases IX and XII in ovarian tumours

Matrix metalloproteinases‐2 and ‐9 in cervical cancer: different roles in tumor progression

Prognostic Significance of Extracellular Matrix Metalloproteinase Inducer and Matrix Metalloproteinase 2 in Epithelial Ovarian Cancer

Evidence of Founder Mutations in Finnish BRCA1 and BRCA2 Families

Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial

0235: Targeting Bevacizumab Treatment in Gynecological Malignancies

Matrix metalloproteinase 9 and relapse in patients with early stage squamous cervical carcinoma

0710: Surveillance of Women at High Risk of Gynecological Cancers: 10 Year Results From One Center

Further evidence for the contribution of the RAD51C gene in hereditary breast and ovarian cancer susceptibility

FINHYST 2006—national prospective 1-year survey of 5 279 hysterectomies

Matrix metalloproteinases-2 and -9 in cervical cancer: different roles in tumor progression

Extracellular matrix interactions in early human embryos: implications for normal implantation events

0076: Primary Surgery at University Hospitals Improves Survival of Ovarian Cancer-A Prospective Nationwide Study in Finland

Gelatinases A and B (MMP-2 and MMP-9) in endometrial cancer—MMP-9 correlates to the grade and the stage

Laminin in the human embryo implantation: analogy to the invasion by malignant cells

Regulation of 72-kd type IV collagenase-matrix metalloproteinase-2 by estradiol and gonadotropin-releasing hormone agonist in human granulosa-lutein cells

SEQUENTIAL GEMCITABINE-CARBOPLATIN (GC) FOLLOWED BY PACLITAXEL-CARBOPLATIN (PC) IN THE FIRST-LINE TREATMENT OF ADVANCED OVARIAN CANCER (OC). A PHASE II TRIAL

Randomized Trial of Single Agent Paclitaxel Given Weekly Versus Every Three Weeks and with Peroral Versus Intravenous Steroid Premedication to Patients with Ovarian Cancer Previously Treated with Platinum

Surgical treatment of ovarian cancer in different hospital categories – A prospective nation-wide study in Finland

Suchergebnisse filtern